Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children

ISSN: 1875-5453 (Online)
ISSN: 1389-2002 (Print)


Volume 15, 10 Issues, 2014


Download PDF Flyer




Current Drug Metabolism

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 68th of 290 in Biochemistry & Molecular Biology
  • 36th of 261 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Chandra Prakash
Department of Drug Metabolism and Pharmacokinetics Biogen Idec Cambridge
MA
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 4.405
5 - Year: 4.508

Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children

Author(s): Patricia Huezo-Diaz, Chakradhara Rao S. Uppugunduri, Anuj Kumar Tyagi, Maja Krajinovic and Marc Ansari

Affiliation: Department of Pediatrics, Onco-Hematology unit; University Hospitals of Geneva, Rue Willy Donzé 6, 1211 Geneva 14, Switzerland.

Abstract

Allogenic hematopoietic stem cell transplantation (HSCT) is a well established but complex treatment option for malignant and non-malignant disorders in pediatric patients. Most commonly used myeloablative and non-myeloablative conditioning regimens in children comprise alkylating agents, such as busulfan (BU) and cyclophosphamide. Inter-individual variability in the pharmacokinetics of BU can result in altered conditioning of the patient and therefore lead to relapse or rejection due to under exposures, or occurrence of toxicities due to over exposures. With the introduction of the intravenous formulation of BU, this variability has been reduced but still cannot be fully predicted. Inter and intra-individual variability of BU kinetics is more common in children compared to adults and toxicity of BU based regimens is still a concern. It has been hypothesized that some of this variability in BU pharmacokinetics and treatment outcomes, especially the toxicity, might be predicted by genetic variants of enzymes involved in the metabolism of BU. This review intends to summarize the studies performed to date on the pharmacokinetics and pharmacogenetics of BU based conditioning, specifically in relation to children.

Keywords: Busulfan, CYP, dose adjustment, GSTA, pharmacogenetics, pharmacokinetics, SNP, sulfolane, TDM.

Download Free Rights and Permissions

Article Details

Volume: 15
Issue Number: 3
First Page: 251
Last Page: 264
Page Count: 14
DOI: 10.2174/1389200215666140202214012
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science